Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$1.94
EPS est.
$1.28
EPS surprise
+51.21%
1-day move
+0.74%
Neurocrine Biosciences reported a strong earnings per share, significantly beating expectations, which contributed to a slight increase in stock price. However, there was no revenue reported, leaving some uncertainty about overall performance. The lack of guidance and management commentary means investors may need to wait for further details to assess future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.94 | $1.71 | +51.21% |
| Revenue | — | $771M | — |
No transcript is on record, and the analysis is based on numerical results only.
Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases. With a market cap of $13 billion, it plays a significant role in the healthcare sector, particularly as demand for innovative therapies continues to grow.
Last quarter
In Q4 2025, Neurocrine reported an EPS of $1.88, exceeding expectations by 5.56%. However, the stock experienced a slight decline the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+37.39%
Avg 1-day reaction
+1.33%
Analysts expect Neurocrine to continue its trend of strong earnings, with a consensus EPS of $1.71 and revenue of $771 million. Investors are keen to see if the company can maintain its positive momentum.
Bull case
If Neurocrine beats EPS and revenue estimates, it could signal strong demand for its products and further validate its growth strategy, potentially boosting investor confidence.
Bear case
Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and market competitiveness, leading to a negative reaction in the stock price.
Key metrics to watch
EPS
$1.71Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.
Revenue
$771MTotal revenue reflects the company's ability to sell its products and is crucial for assessing growth and market demand.
The print will turn on these.
Q1
Will EPS exceed $1.71, and if so, by how much?
A strong EPS performance could reinforce investor confidence and suggest robust demand for Neurocrine's products.
Q2
What is the revenue outlook for the upcoming quarters?
Guidance on revenue will be crucial for assessing the company's growth trajectory and market position.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate the potential for Neurocrine's new product pipeline to drive revenue growth beyond current projections.
Supporting evidence
Historical performance shows a consistent ability to exceed EPS estimates, suggesting a strong operational foundation.
The options market indicates heightened expectations for volatility, which could reflect investor optimism not fully captured in analyst estimates.
Key risk
If revenue growth significantly outpaces expectations, it could challenge the current consensus view.
Pre-commit to what would confirm each case.
The market is closely watching how Neurocrine's performance aligns with analyst expectations, particularly in a competitive biotech landscape.
Bull confirmed if
An EPS of $1.80 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $1.50 would raise concerns about profitability and growth potential.
What the market is pricing for the move.
Implied Move
±10.95%
Historical Avg
±1.7%
The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.
Options are pricing ±10.2% while NBIX has averaged ±1.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
27.4%
Smart-money positioning from the most recent 13F filings.
Institutional
102.86%
of float
Insider
1.06%
of float
Holders
1,126
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
13,711,607 sh · $2.0B
13.49%
2.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Neurocrine beats expectations, history suggests a positive stock reaction, averaging a +2.44% move.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors assess management's commentary.
Miss
A miss could lead to a negative reaction, with historical averages suggesting a decline of around -2.44%.
The lines on the call that would change the story.
JPMORGAN CHASE & CO
6,398,674 sh · $918.0M
6.29%
17.6%
Dodge & Cox Inc.
5,584,707 sh · $801.2M
5.49%
2.3%
Vanguard Portfolio Management LLC
4,974,083 sh · $713.6M
4.89%
5.2%
Vanguard Capital Management LLC
4,545,339 sh · $652.1M
4.47%
0.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.